2,6-Diaminopurine

2,6-Diaminopurine

SCHEMBL24052

Nc1nc(N)c2nc[nH]c2n1

nearest known ligand 0.48

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GDA Q9Y2T3 2/20 0.48
PDPK1 O15530 1/20 0.48
ADORA2A P29274 1/20 0.42
CDK2 P24941 4/20 0.37
DPP4 P27487 1/20 0.37
ALDH1A1 P00352 2/20 0.35
CDK1 P06493 3/20 0.34
CCNB1 P14635 3/20 0.34
CCNE1 P24864 2/20 0.34
MAP3K5 Q99683 1/20 0.34
DHFR P00374 2/20 0.33
XDH P47989 2/20 0.32
USP2 O75604 1/20 0.32
TP53 P04637 1/20 0.32
ADORA3 P0DMS8 1/20 0.32
HPGD P15428 1/20 0.32
PTGS1 P23219 1/20 0.32
MAPK3 P27361 1/20 0.32
HBB P68871 1/20 0.32
PAX8 Q06710 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
2,6-Diaminopurine SCHEMBL29444619 1.00 GDA (0.48) GDAPDPK1ADORA2ACDK2DPP4
2,6-Diaminopurine SCHEMBL8757968 0.98 GDA (0.47) GDAPDPK1ADORA2ACDK2DPP4
2,6-Diaminopurine SCHEMBL6423146 0.98 GDA (0.47) GDAPDPK1ADORA2ACDK2DPP4
2,6-Diaminopurine SCHEMBL5017251 0.91 PDPK1 (0.42) GDAPDPK1ADORA2ACDK2CDK1
2,6-Diaminopurine SCHEMBL1033680 0.91 GDA (0.42) GDAPDPK1ADORA2ACDK2DPP4
2,6-Diaminopurine SCHEMBL7659157 0.89 GDA (0.41) GDAPDPK1ADORA2ACDK2DPP4
2,6-Diaminopurine SCHEMBL1074475 0.89 GDA (0.41) GDAPDPK1ADORA2ACDK2DPP4
2,6-Diaminopurine SCHEMBL1931238 0.86 PDPK1 (0.39) GDAPDPK1ADORA2ACDK2DPP4
2,6-Diaminopurine SCHEMBL1825527 0.83 ALDH1A1 (0.50) GDAPDPK1ALDH1A1XDHUSP2
SCHEMBL8485064 0.82 PDPK1 (0.36) GDAPDPK1CDK2DPP4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 64129 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146273-A1 METHOD FOR ONE-POT BIOSYNTHESIS OF ARABINONUCLEOSIDE, AND COMPOSITION ASYMCHEM LIFE SCIENCE (TIANJIN) CO., LTD. (CN) 2026-05-28 US claimed
US-20260144879-A1 ANTI-VIRAL AND HEPATIC-TARGETED DRUGS AI-BIOPHARMA (FR) 2026-05-28 US claimed
WO-2026106497-A2 FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) 2026-05-21 WO claimed
US-12630827-B2 Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies ROGCON, INC. (US) 2026-05-19 US claimed
US-20260124274-A1 METHODS OF INCREASING READTHROUGH OF A PREMATURE TERMINATION CODON UNIV RAMOT (IL) 2026-05-07 US claimed
US-20260117116-A1 COMPOSITION AND METHOD FOR HYDRAULIC FRACTURING AND EVALUATION AND DIAGNOSTICS OF HYDRAULIC FRACTURES USING INFUSED POROUS CERAMIC PROPPANT CARBO CERAMICS INC (US) 2026-04-30 US claimed
WO-2026090528-A2 CIRCULARLY STRUCTURED GUIDE RNAS FOR CRISPR GENOME EDITING UNIVERSITY OF MASSACHUSETTS (US) 2026-04-30 WO claimed
US-20260117285-A1 COMPOSITIONS AND METHODS FOR IMPROVING LIBRARY ENRICHMENT ILLUMINA INC (US) 2026-04-30 US claimed
US-20260109977-A1 MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION TRILINK BIOTECHNOLOGIES, LLC (US) 2026-04-23 US claimed
US-12605400-B2 Oligomeric nucleic acid molecule, and application thereof in an acute intermittent porphyria treatment RACTIGEN THERAPEUTICS (CN) 2026-04-21 US claimed
EP-0269947-A1 Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CS) 1988-06-08 EP claimed
EP-0254268-A2 Fluorinated nucleosides,their preparation and their pharmaceutical use against AIDS THE WELLCOME FOUNDATION LIMITED (GB) 1988-01-27 EP claimed
EP-0117777-B1 COMPOUNDS CONTAINING AN OLIGONUCLEOTIDE BONDED TO AN INTERCALLATING AGENT, A PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1987-12-23 EP claimed
US-4670424-A Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides MERCK & CO., INC. (US) 1987-06-02 US claimed
EP-0214908-A1 Compounds containing an oligonucleotide sequence linked to an intercalating agent and to an activable chemical group, their synthesis and applications to artificial sequence-specific nucleases CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1987-03-18 EP claimed
WO-1986003678-A1 COMPOSITION AND METHOD FOR TREATMENT OF TUMORS WITH UDPG MEMORIAL HOSPITAL FOR CANCER AND ALLIED DISEASES (US) 1986-07-03 WO claimed
EP-0169787-A1 Use of oligonucleotides bonded to an intercalating agent as drugs CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1986-01-29 EP claimed
EP-0138656-A1 Cyclic pyrophosphates of purine and pyrimidine acyclonucleosides, their preparation and their application in anti-viral compositions MERCK & CO. INC. (US) 1985-04-24 EP claimed
US-4060616-A VIRICIDE BURROUGHS WELLCOME CO. (US) 1977-11-29 US claimed
US-4002532-A BINDING ANTIBODIES WELTMAN JOEL K 1977-01-11 US claimed